Poster Viewing Sessions

Poster Viewing Sessions are organised on Monday 16, Tuesday 17, Wednesday 18 and Thursday 19 November.

During those sessions, Young investigators will reply live and by chat to questions moderated by the session chairs following the broadcasting of their video recorded poster presentation via the live stream.

Title Location
Poster Viewing Session I - Basic Studies
Prof Dr Hans Lassmann, Prof Dr Hartmut Wekerle
15:30 ID 28: Endocannabinoid system modulation in peripheral blood mononuclear cells from dimethyl fumarate-treated multiple sclerosis patients
Ms Alicia Sánchez Sanz
15:36 ID 36: Anterior optic pathway pathology in CNS demyelinating diseases
Dr Marco Pisa
15:42 ID 45: Is EBV DNA detectable in CSF in multiple sclerosis?
Mr Joonas Lehikoinen
15:48 ID 54: Fluoxetine modulates Th17-immune response via 5-HT2B-receptors in multiple sclerosis
Dr Mikhail Melnikov
15:54 ID 57: Dopamine suppresses Th17-cells function in multiple sclerosis
Dr Mikhail Melnikov
16:00 ID 62: Effects of different Myelin Oligodendrocyte Glycoprotein dosage on visual function in the Dark Agouti rat model of Experimental Autoimmune Encephalomyelitis
Dr Valerio Castoldi
16:06 ID 77: A case of autoimmune GFAP astrocytopathy diagnosed after long term diagnosis of CLIPPERS
Dr Hexiang Yin
16:12 ID 87: Laboratory detection of antibody in IIDDs
Dr Li-Jie Zhang
16:18 ID 95: Direct conversion of mouse embryonic fibroblasts toward oligodendrocyte precursor cells
Dr Maryam Ghasemi
Poster Viewing Session II - Treatment I
Prof Dr Jacqueline Palace, Prof Dr Xavier Montalban
16:30 ID 5: Inhalation of Dimethyl Fumarate encapsulated-nanoparticles attenuates clinical signs and central nervous system inflammation of Experimental Autoimmune Encephalomyelitis animals’ models
Mrs Bárbara Pinto
16:36 ID 6: Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting
Dr Huah Shin Ng
16:42 ID 9: Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with Multiple Sclerosis.
Dr Serena Borrelli
16:48 ID 11: Effects of smoking on lymphocyte subpopulations in patients with MS on dimethyl fumarate
Ms Maria-Elizabeth Baeva
16:54 ID 14: Characterization of cladribine tablets treated MS patients in Finland
Mr Ilkka Rauma
Title Location
Poster Viewing Session III - Investigations
Prof Dr Ludwig Kappos, Prof Dr Letizia Leocani
15:30 ID 8: Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis
Dr Ismail Koubiyr
15:36 ID 23: MR T2-relaxation time as an indirect measure of brain water accumulation in Neuromyelitis Optica Spectrum Disorders
Dr Laura Cacciaguerra
15:42 ID 52: Retinal neuro-axonal loss parallels global disability accrual in progressive multiple sclerosis independently from disease activity
Dr Simone Guerrieri
15:48 ID 56: Serum neurofilaments predict recovery after acute optic neuritis
Dr Gloria Dalla Costa
15:54 ID 63: Functional and structural visual pathway alterations in experimental autoimmune encephalomyelitis mouse model
Dr Silvia Marenna
16:00 ID 64: The relationship between cerebellar volume, clinical disability and cognitive changes in MS patients
Dr Onural Ozturk
16:06 ID 86: The cerebellar peduncle lesion as an age-independent feature of MOG antibody associated disease
Dr Yuki Matsumoto
16:12 ID 88: SWI enhances vein detection using UPSIO in multiple sclerosis
Dr Li-Jie Zhang
Poster Viewing Session IV - Treatment II
Prof Dr Patrick Vermersch, Prof Dr Hans-Peter Hartung
16:20 ID 16: Propensity-matched comparison of early intensive and escalation treatment strategy in Finnish MS patients
Dr Katariina Hänninen
16:26 ID 20: Assessing the real-world effectiveness of ocrelizumab in patients with multiple sclerosis – CONFIDENCE one-year interim analysis
Dr Julius Eggebrecht
16:32 ID 21: Safety and tolerability in patients with multiple sclerosis receiving ocrelizumab in a real-world setting – CONFIDENCE one-year interim analysis
Dr Julius Eggebrecht
16:38 ID 43: Secondary Autoimmune Diseases following Ocrelizumab Therapy for Multiple Sclerosis
Dr Sophie Elands
16:44 ID 58: Therapeutic Plasma Exchange Effect on Neuromyelitis Optica Spectrum Disorder
Dr Enrique Gomez-Figueroa
17:00 ID 71: Rituximab in Multiple Sclerosis: B-lymphocyte population study and its relationship with dosing regimen
Dr Inês Cunha
Title Location
Poster Viewing Session V - Clinical I
Prof Dr Alexey Boyko, Prof Dr Edgardo Cristiano
15:30 ID 3: Stable vs. Silent progressive Multiple Sclerosis: A real world retrospective clinical imaging Brazilian study
Ms Raquel Custódio Da Silveira
15:36 ID 12: Information in Multiple Sclerosis: do people with MS want to know about their disease?
Dr Elisa Matias Vieira de Melo
15:42 ID 26: Efficacy of high-intensity aerobic exercise on fatigue, walking, and quality of life in people with multiple sclerosis: A randomized controlled trial
Dr Martin Langeskov-Christensen
15:48 ID 39: Concomitant onset of Multiple Sclerosis and celiac disease: association or new disease entity?
Dr Gaia Cola
15:54 ID 42: Anti-NMDAR autoimmune encephalitis in Covid-19 pneumonia patient
Dr Erasmo Ramos
16:00 ID 44: The Concurrence of Multiple Sclerosis and Glioma
Dr Sophie Elands
Poster Viewing Session VI - Epidemiology I
Prof Dr Oscar Fernández, Prof Per Soelberg Sørensen
16:10 ID 2: Smoking and multiple sclerosis risk: A Mendelian randomization study
Ms Marijne Vandebergh
16:16 ID 4: Demographic poor prognostic factors in Mexican patients with multiple sclerosis
Dr Ricardo García-Bermúdez
16:22 ID 17: Multiple Sclerosis after Primary Central Nervous System Cancer in Mexican Population
Dr Marlene Arbeu-Reyes
16:28 ID 25: Functional survey of the pediatric multiple sclerosis microbiome
Mr Ali Mirza
16:34 ID 29: A systematic review and meta-analysis of the prevalence of multiple sclerosis in patients with uveitis and characterisation of the phenotype of patients with both conditions
Dr Thomas Taylor
16:40 ID 35: Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes
Dr Marco Pisa
16:46 ID 47: Probing gene-environment interactions in the pathogenesis of Multiple Sclerosis using UK Biobank
Dr Benjamin Jacobs
Title Location
Poster Viewing Session VII - Clinical II
Bernard M.J. Uitdehaag, Prof Dr Gilles Edan
15:30 ID 50: Identifying distinct cognitive phenotypes in multiple sclerosis
Dr Ermelinda De Meo
15:36 ID 53: Central and peripheral (CCDP) demyelination in a patient with MOGAD disease(MOG Antibody disease)
Mr Konstantinos Melanis
15:42 ID 60: Diffuse B giant cell lymphoma associated with fingolimod treatment in Multiple Sclerosis: a case report
Dr Adriana Casallas Vanegas
15:48 ID 65: A Genome-Wide Association Study highlights a possible involvement of mast cells and neutrophils in disease activity in multiple sclerosis
Dr Antonino Giordano
15:54 ID 70: Predominant cognitive phenotypes in MS: insights from patient-centered outcomes (PCOs)
Dr Jessica Podda
16:00 ID 84: Clinical characteristics of patients with late-onset NMOSD in a Japanese cohort
Mr Akihiro Nakajima
Poster Viewing Session VIII - Epidemiology II
Prof Dr Maria Trojano, Prof Dr Kazuo Fujihara
16:15 ID 49: Cardiovascular risk factors affect brain volume in young multiple sclerosis patients
Dr Raffaello Bonacchi
16:21 ID 59: Multiple Sclerosis-related Optic Neuritis: A retrospective observational study
Dr Sofia Bezerra de Oliveira Costa
16:27 ID 61: Comorbidity and persistence of disease-modifying therapy use for relapsing remitting multiple sclerosis
Dr Natalie Parks
16:33 ID 66: Fine particulate matter related to multiple sclerosis relapse in young patients
Dr Edouard Januel
16:39 ID 69: Is salt consumption an environmental risk factor for multiple sclerosis?
Dr Sena Destan Bunul
16:45 ID 72: MS risk/protection factors: A Moroccan study
Dr Hind Gouiti